Jean‐Yves Douillard

33.5k citations
266 papers · 17.1k · 10 hit papers · h-index 55

Impact in

  • Oncology top 0.1%
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Research Studies
    • HER2/EGFR in Cancer Research
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Gastric Cancer Management and Outcomes

Papers in

    • Colorectal Cancer Treatments and Studies 128
    • Cancer Treatment and Pharmacology 56
    • Lung Cancer Research Studies 28
    • Lung Cancer Treatments and Mutations 99
    • Gastric Cancer Management and Outcomes 37
    • Lung Cancer Diagnosis and Treatment 25

Jean‐Yves Douillard

266 papers receiving 16.6k citations

Jean‐Yves Douillard's Hit Papers

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status 2014 · 348 citations
3480+11+23Years since publication50010001.5k2.0k

Peers

Jean‐Yves Douillard
Comparison fields: 5 of 124
  • Oncology 8.3k
  • Pulmonary and Respiratory Medicine 7.7k
  • Hepatology 1.5k
  • Cancer Research 1.7k
  • Pathology and Forensic Medicine 1.3k
Replace Fairooz F. Kabbinavar with:
Fairooz F. Kabbinavar United States
David R. Spigel United States
Ian Chau United Kingdom
J. Wanders Netherlands
Lucio Crinò Italy
Joon Oh Park South Korea
Federico Cappuzzo Italy
Joachim von Pawel Germany
Gabriella Fontanini Italy
Marc Ychou France
Jean‐Yves Douillard relative to Fairooz F. Kabbinavar United States Fairooz F. Kabbinavar's profile →
Citations per field
00.5×1.5×
Fairooz F. Kabbinavar · 1×
Citations per year

Countries citing papers authored by Jean‐Yves Douillard

Since Specialization
Citations

This map shows the geographic impact of Jean‐Yves Douillard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Yves Douillard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Yves Douillard more than expected).

Fields of papers citing papers by Jean‐Yves Douillard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Yves Douillard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Yves Douillard. The network helps show where Jean‐Yves Douillard may publish in the future.

Co-authors

The 25 scholars most cited alongside Jean‐Yves Douillard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jean‐Yves Douillard Line = papers co-authored together Jean‐Yves Douillard links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 266 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Hit paper breakdown →
20032389
2
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Hit paper breakdown →
20101355
3
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Hit paper breakdown →
20081012
4
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Hit paper breakdown →
2006951
5
Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma
Hit paper breakdown →
1998741
6
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Hit paper breakdown →
2014697
7
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
Hit paper breakdown →
1994679
8
Radiotherapy Alone Versus Combined Chemotherapy and Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a Randomized Trial in 353 Patients
Hit paper breakdown →
1991621
9
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
Hit paper breakdown →
2014348
10
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
Hit paper breakdown →
2014290
11 2007284
12 2011275
13 2002273
14 2002249
15 2008248
16 2002237
17
Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma.
1983221
18 1991213
19 2012187
20 2008161

About Jean‐Yves Douillard

Jean‐Yves Douillard is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 266 papers that have together received 17.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (128 papers), Lung Cancer Treatments and Mutations (99 papers), Cancer Treatment and Pharmacology (56 papers), Gastric Cancer Management and Outcomes (37 papers), Lung Cancer Research Studies (28 papers), Cancer Genomics and Diagnostics (27 papers), Lung Cancer Diagnosis and Treatment (25 papers) and Hepatocellular Carcinoma Treatment and Prognosis (20 papers). The work is most often cited by research in Oncology (8.3k citations), Pulmonary and Respiratory Medicine (7.7k citations), Hepatology (1.5k citations), Cancer Research (1.7k citations) and Pathology and Forensic Medicine (1.3k citations). Jean‐Yves Douillard has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Thierry Le Chevalier, Salvatore Siena, Kazuhiko Nakagawa, Martin Reck, Giuseppe Giaccone, Sylvie Négrier, Egbert F. Smit, Bernard Escudier, Shinzoh Kudoh and Frances A. Shepherd. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Lung Cancer, European Journal of Cancer and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact